secwatch.observer — SEC 8-K summary
======================================

Issuer:     MoonLake Immunotherapeutics (MLTX)
CIK:        0001821586
Form:       8-K
Filed at:   2023-06-26T23:59:59+00:00
Accession:  0001628280-23-023381
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MoonLake's sonelokimab hits HiSCR75 with 29 ppt delta (p=0.0002) in Phase 2 HS trial
--------------------------------------------------------------------------------

- Primary endpoint HiSCR75 met with 29 ppt delta vs placebo (p=0.0002) at week 12.
- HiSCR50 achieved 38 ppt delta (p<0.0001), highest delta observed for any molecule in HS.
- Secondary endpoints including HiSCR90, IHS4, and patient-reported pain/quality of life met statistical significance.
- Safety profile consistent with known IL-17 inhibitor class; no new safety signals observed.
- Dose of 120mg performed similarly to 240mg; 120mg considered optimal for further development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821586/000162828023023381/0001628280-23-023381-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821586/000162828023023381/mltx-20230626.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-023381

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer